@Article{Jurczak2015,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="19",
number="1",
year="2015",
title="The use of Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation",
abstract=" Aim of the study : To evaluate the efficacy and safety of Yttrium-90 Ibritumomab Tiuxetan ( 90 Y-IT) as a consolidation therapy in the management of DLBCL.    Material and methods : Patients with primary refractory or high-risk DLBCL (n = 18), ineligible for autologous stem-cell transplantation, were included in a retrospective study performed at three centers by the Polish Lymphoma Research Group (PLRG). All patients (mean age 61, range 35–82) either didn’t achieve a complete response or didn’t complete the scheduled therapy due to its complications. Response rates (CR, PR, SD, PD) according to Cheson criteria, overall survival (OS), progression-free survival (PFS) and adverse effects of radioimmunotherapy were analyzed.   Results:  Consolidation radioimmunotherapy increased the CR rate from 38% (n = 7) to 82% (n = 15). One pa­tient remained in PR, one patient remained in SD, while one patient remained in PD. During a median follow-up of five years, 11 patients (62%) were alive with no recurrence, 4 patients (22%) were alive with relapse while 3 patients (16%) died. There was no statistically significant difference in PFS between those in CR and those in PR before  90 Y-IT.    Conclusions : Radioimmunotherapy is an effective consolidation therapy for high risk/refractory DLBCL patients and worthy of further investigation in prospective trials.",
author="Jurczak, Wojciech
and Kisiel, Elżbieta
and Sawczuk-Chabin, Joanna
and Centkowski, Piotr
and Knopińska-Posłuszny, Wanda
and Khan, Omeir",
pages="43--47",
doi="10.5114/wo.2015.50012",
url="http://dx.doi.org/10.5114/wo.2015.50012"
}